157 related articles for article (PubMed ID: 34013846)
1. High PRAME expression is associated with poor survival and early disease progression in myelodysplastic syndromes with a low bone marrow blast percentage.
Shiseki M; Ishii M; Ohwashi M; Wang YH; Tanaka N; Osanai S; Yoshinaga K; Mori N; Tanaka J
Leuk Lymphoma; 2021 Oct; 62(10):2448-2456. PubMed ID: 34013846
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.
Huang QS; Wang JZ; Qin YZ; Zeng QZ; Jiang Q; Jiang H; Lu J; Liu HX; Liu Y; Wang JB; Su L; Zhang HY; Li ZL; Gao SJ; Huang B; Liu YY; Liu YR; Xu LP; Huang XJ; Zhang XH
Blood Adv; 2019 Nov; 3(21):3406-3418. PubMed ID: 31714962
[TBL] [Abstract][Full Text] [Related]
3. [Expression of WT1 and PRAME gene in bone marrow and peripheral blood samples of patients with myelodysplastic syndrome].
Lu D; Qin YZ; Li LD; Shi HX; Lai YY; Liu YR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):370-6. PubMed ID: 24763007
[TBL] [Abstract][Full Text] [Related]
4. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes.
Tong H; Hu C; Zhuang Z; Wang L; Jin J
Leuk Lymphoma; 2012 Dec; 53(12):2412-8. PubMed ID: 22632108
[TBL] [Abstract][Full Text] [Related]
6. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
7. Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes.
Wu A; Gao P; Wu N; Shi C; Huang Z; Rong C; Sun Y; Sheng L; Ouyang G; Mu Q
BMC Cancer; 2021 May; 21(1):546. PubMed ID: 33985456
[TBL] [Abstract][Full Text] [Related]
8. PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes.
Qin YZ; Zhu HH; Liu YR; Wang YZ; Shi HX; Lai YY; Xu LP; Liu DH; Jiang Q; Li LD; Jiang B; Liu KY; Huang XJ
Leuk Lymphoma; 2013 Jul; 54(7):1442-9. PubMed ID: 23110703
[TBL] [Abstract][Full Text] [Related]
9. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
10. The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons.
Baba M; Hata T; Tsushima H; Mori S; Sasaki D; Turuta K; Hasegawa H; Ando K; Sawayama Y; Imanishi D; Taguchi J; Yanagihara K; Tomonaga M; Kamihira S; Miyazaki Y
Intern Med; 2015; 54(5):445-51. PubMed ID: 25758068
[TBL] [Abstract][Full Text] [Related]
11. Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy.
Gauthier J; Damaj G; Langlois C; Robin M; Michallet M; Chevallier P; Beguin Y; N'guyen S; Bories P; Blaise D; Cornillon J; Clavert A; Mohty M; Huynh A; Thiébaut-Bertrand A; Vigouroux S; Duhamel A; Yakoub-Agha I
Transplantation; 2015 Aug; 99(8):1672-80. PubMed ID: 25769079
[TBL] [Abstract][Full Text] [Related]
12. Prognostic evaluation of ALIP and CD34 immunostaining in IPSS-R subgroups of myelodysplastic syndromes.
Xiong B; Nie Y; Tang Z; Xue M; Zuo X
Pathology; 2017 Aug; 49(5):526-533. PubMed ID: 28669578
[TBL] [Abstract][Full Text] [Related]
13. High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.
Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
Br J Haematol; 2014 Oct; 167(1):100-9. PubMed ID: 24976502
[TBL] [Abstract][Full Text] [Related]
14. Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry.
Kawabata H; Tohyama K; Matsuda A; Araseki K; Hata T; Suzuki T; Kayano H; Shimbo K; Zaike Y; Usuki K; Chiba S; Ishikawa T; Arima N; Nogawa M; Ohta A; Miyazaki Y; Mitani K; Ozawa K; Arai S; Kurokawa M; Takaori-Kondo A;
Int J Hematol; 2017 Sep; 106(3):375-384. PubMed ID: 28497239
[TBL] [Abstract][Full Text] [Related]
15. Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?
Greenbaum U; Joffe E; Filanovsky K; Oster HS; Kirgner I; Levi I; Raanani P; Avivi I; Manor E; Man-El G; Mittelman M
Eur J Haematol; 2018 Oct; 101(4):502-507. PubMed ID: 29956845
[TBL] [Abstract][Full Text] [Related]
16. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
[TBL] [Abstract][Full Text] [Related]
17. [Scoring analysis on prognosis of 63 patients with melodysplastic syndrome].
Wei J; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):305-11. PubMed ID: 18426654
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia.
Wang H; Wang XQ; Xu XP; Lin GW
Eur J Haematol; 2009 Dec; 83(6):550-8. PubMed ID: 19737310
[TBL] [Abstract][Full Text] [Related]
19. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
20. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.
Verburgh E; Achten R; Maes B; Hagemeijer A; Boogaerts M; De Wolf-Peeters C; Verhoef G
J Clin Oncol; 2003 Jan; 21(2):273-82. PubMed ID: 12525519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
